DxLab Inc. (DxLab) is a biotech startup, spun out of MIT and Harvard in September 2020, developing and commercializing a next-generation point-of-care (POC) diagnostic solution for rapid, on-site detection of dangerous pathogens. Combining proprietary platform technology with novel target detection and signal processing methods, we are advancing a pipeline of rapid POC tests.
Murata is seeking startups to trial its innovative cell fractionation filter, CELLNETTA, to identify key challenges this product can solve.
Xinterra pioneered the combined use of high throughput experimentation and artificial intelligence applied to materials, seeking efficient approaches to overcome slowness, high costs and overall limitation to innovation imposed by traditional materials R&D processes. Buonassisi will discuss Xinterra's combined use of high throughput experimentation and artificial intelligence applied to materals.